Treatment of early AIDS dementia in intravenous drug users: High versus low dose peptide T

American Journal of Drug and Alcohol Abuse

Volumn 23, Issue 4, 1997, Pages 543-553

  Kosten, Thomas R ^a   Rosen, Marc I ^b   McMahon, Thomas L ^b   Bridge, T Peter ^b   O'Malley, Stephanie S ^b   Pearsall, Rowland ^b   O'Connor, Patrick G ^b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; PEPTIDE T; PLACEBO; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMENTIA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ABUSE; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST;

EID: 0030713105     PISSN: 00952990     EISSN: None     Source Type: Journal    
DOI: 10.3109/00952999709016894     Document Type: Article

References (38)

1. Navia, B. A., Jordan, B. D., and Price, R. W., The AIDS dementia complex: I. Clinical features. Am. Neurol. 19:517-524 (1986).
2. Navia, B. A., Cho, E., Peptito, C. K., et al., The AIDS dementia complex: II. Neuropathology, Ann. Neurol. 19:525-535 (1986).
3. Price, R. W., Brew, B., and Sidtis, J., The brain in AIDS: Central nervous system HIV-I infection and AIDS dementia complex, Science 89:586-592 (1988).
4. Price, R. W., and Brew, B. J., The AIDS dementia complex, J. Infect. Dis. 158:1079-1083 (1989).
5. Bridge, T. P., HIV-1: Neuropsychiatric manifestations and their treatment, Psychopharmacol. Bull. 23:320-324 (1988).
6. Wiley, C. A., Schrier, R. D., Nelson, J. A., et al., Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency patients, Proc. Natl. Acad. Sci. USA 83:7089-7093 (1986).
7. Bridge, T. P., Heseltine, P. N., and Parker, E. S., Improvement in AIDS patients on Peptide T, Lancet 1:226-227 (1989).
8. Bridge, T. P., Heseltine, P. N., Parker, E. S., et al., Results of extended Peptide T administration in AIDS and ARC patients, Psychopharmacol. Bull. 27:237-245 (1991).
9. Bridge, T. P., Linde, R., Ollo, C., et al., Neuropsychologic results of control HIV-1 trial of Peptide T, Seventh International Conference on AIDS, Florence, Italy, June 1991.
10. Rosen, M. I., Bridge, T. P., O'Malley, S. S., et al., Peptide T treatment of cognitive impairment in HIV seropositive intravenous drug users, Am. J. Addict. 1:1-7 (1992).
11. Schmitt, F. A., Bigley, J. W., McKinnis, R., et al., Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex, N. Engl. J. Med. 319:1573-1578 (1988).
12. Portegies, P., DeGans, J., Lange, J. M., et al., Declining incidence of AIDS dementia complex after introduction of zidovudine treatment, B.M.J. 299:819-821 (1989).
13. Yarochan, R., Thomas, R. V., Grafman, J., et al., Long-term administration of 3′-zido-2′3′-dideoxythymidine to patients with AIDS-related neurological disease, Ann. Neurol. 23:S82-S87 (1988).
14. Elovaara, I., Poutianinen, E., Lahdevirta, J., and Hokkanen, L., Zidovudine reduces intrathecal immoactivation in patients with early human immunodeficiency virus type I infection, Finland Arch. Neurology 51:943-950 (1994).
15. Karlsen, N. R., Reinvang, I., and Froland, S. S., A follow-up study of neuropsychological functioning in AIDS-patients: Prognostic significance and effect of zidovudine therapy, Acta Neurologica Scandinavica 91:215-221 (1995).
16. Wechsler, D., Wechsler Adult Intelligence Scale-Revised, Psychological Corporation, New York, 1981.
17. Dunn, L. M., and Markwardt, F. C., PIAT: Peabody Individual Achievement Test, American Guidance Service, Circle Pines, Minnesota 1970.
18. Reitan, R. M., and Wolfson, D., The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation, Neuropsychology Press, Tucson, Arizona, 1985.
19. Lezak, M. D., Neuropsychological Assessment, Oxford University Press, New York, 1983.
20. Lafayette Instrument Company., Instructions for the Grooved Pegboard Test, Lafayette Instrument Company, Lafayette, Indiana, 1989.
21. Golden, C. J., The Stroop Color and Word Test: A Manual for Clinical and Experimental Uses, Stoelting Company, Chicago, Illinois, 1978.
22. Levin, H. S., Mattis, S., Ruff, R. M., et al., Neurobehavioral outcome following minor head injury: A three center study, J. Neurosurgery 66:234-243 (1987).
23. Gronwall, D., Paced auditory serial addition task: A measure of recovery from concussion, Percept. Mot. Skills 44:367-373 (1977).
24. Roman, D. D., Edwall, G. E., Buchman, R. J., et al., Extended norms for the Paced Auditory Serial Addition Task, Clin. Neuropsychologist 5:33-40 (1991).
25. Ingraham, L. J., and Bridge, T. P., An empirical approach to determining criteria for abnormality in test batteries with multiple measures, Neuropsychology 10:120-124 (1996).
26. Benton, A. L., and Hamsher, K. D., Multilingual Aphasia Examination (Second Edition), University of Iowa, Iowa City, 1976.
27. Yeudall, L. T., Fromm, D., Reddon, J. R., et al., Normative data stratified by age and sex for 12 neuropsychological tests, J. Consult. Clin. Psychology 42:918-946 (1986).
28. Heaton, R. K., Grant, I., and Matthews, C. G., Comprehensive Norms for an Extended Halstead-Reitan Battery: Demographic Corrections, Research Findings, and Clinical Applications, Psychological Assessment Resources, Odessa, Florida, 1991.
29. Parker, E. S., Bridge, T., Ingraham, L., et al., Neurotoxicity battery for phase I HIV drug assessment: Initial applications. Int. Conf. AIDS 5(2):462 (1989).
30. Lewis, R. F., and Rennick, P. M., Manual for the Repeatable Cognitive Perceptual-Motor Battery, Axon Publishing, Grosse Pointe Park, Mississippi, 1979.
31. Siberstein, C. H., O'Dowd, M. A., Chartock, P., et al., A prospective four-year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients, Gen. Hosp. Psychiatry 15:351-359 (1993).
32. Egan, V., Brettle, R. P., and Goodwin, G. M., The Edinburgh cohort of HIV-positive drug users: Patterns of cognitive impairment in relation to progression of disease, British J. Psychiatry 161:522-531 (1992).
33. McKegney, F. P., O'Dowd, M. A., Feiner, C., et al., A prospective comparison of neuropsychologic function in HIV-seropositive and seronegative methadone-maintained patients, AIDS 4:565-569 (1990).
34. Heaton, R. K., Grant, I., Butters, N., et al., The HNRC 500: Neuropsychology of HIV infection at different disease stages, J. Int. Neuropsychological Society 1:231-251 (1995).
35. Beason-Hazen, S., Nasrallah, H. A., Bornstein, R. A., Self-report of symptoms and neuropsychological performance in asymptomatic HIV-positive individuals, J. Neuropsychiatry Clin. Neurosciences 6:43-49 (1994).
36. van Gorp, W. G., Hinkin, C., Satz, P., et al., Subtypes of HIV-related neuropsychological functioning: A cluster analysis approach, Neuropsychology 7:62-72 (1993).
37. van Dyck, C. H., McMahon, T. J., Rosen, M. I., et al., Sustained-release methylphenidate for cognitive impairment in HIV-infected drug abusers: A pilot study, J. Neuropsychiatry Clin. Neurosciences, In Press.
38. Peterson, P. K., Sharp, B. M., Gekker, G., et al., Opiates, human peripheral blood mononuclear cells, and HIV, Advances in Experimental Medicine Biology 288:171-178 (1991).